Healthcare News

Teva Pharmaceuticals proposes acquiring BXCL501, expanding its neuroscience portfolio with a novel agitation treatment under FDA review

ASHBURN, Va., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical-stage specialty pharmaceutical company focused on rare and...

Quoin Pharmaceuticals (NASDAQ: QNRX) interim Phase 2/3 data in Netherton Syndrome met the primary endpoint, with four of six patients responding.

BioXcel Therapeutics intends to complete a court-supervised sale transaction, in an effort to maximize value for all stakeholders Teva Pharmaceuticals to serve as “stalking horse” bidder in a...

CDT Validates Enhanced Solid-Form Properties Within Its IP Portfolio

-- Chiesi’s abstract presentations highlight clinical insights and patient-reported outcomes in Fabry disease and alpha-mannosidosis -- -- Rooted in patient voice and scientific rigor, this research...

The SALWEEN study showed significant improvements in vision and retinal health1 More than 60% of Asian patients with polypoidal choroidal vasculopathy (PCV), an aggressive subtype of nAMD, treated...

-- Chiesi’s abstract presentations highlight clinical insights and patient-reported outcomes in Fabry disease and alpha-mannosidosis -- -- Rooted in patient voice and scientific rigor, this research...

EssilorLuxottica announces the launch of a share buyback program Paris, France (August 28, 2026 – 8:00am) – EssilorLuxottica announces the launch of a share buyback program, reflecting the Group’s...

EssilorLuxottica annonce le lancement d’un programme de rachat d’actions Paris, France (28 août 2026 – 8h00) – EssilorLuxottica annonce le lancement d’un programme de rachat d’actions qui traduit la...